company background image
5317

Gennex Laboratories BSE:531739 Stock Report

Last Price

₹6.60

Market Cap

₹834.9m

7D

-2.9%

1Y

-44.5%

Updated

06 Jul, 2022

Data

Company Financials
531739 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance2/6
Financial Health5/6
Dividends0/6

531739 Stock Overview

Gennex Laboratories Limited engages in manufacturing and selling of bulk drugs, intermediates, and biotech products.

Gennex Laboratories Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Gennex Laboratories
Historical stock prices
Current Share Price₹6.60
52 Week High₹12.90
52 Week Low₹6.03
Beta0.58
1 Month Change-2.08%
3 Month Change-21.80%
1 Year Change-44.54%
3 Year Change98.20%
5 Year Change37.21%
Change since IPO450.00%

Recent News & Updates

Shareholder Returns

531739IN PharmaceuticalsIN Market
7D-2.9%0.9%1.6%
1Y-44.5%-16.4%0.8%

Return vs Industry: 531739 underperformed the Indian Pharmaceuticals industry which returned -16.7% over the past year.

Return vs Market: 531739 underperformed the Indian Market which returned -0.1% over the past year.

Price Volatility

Is 531739's price volatile compared to industry and market?
531739 volatility
531739 Average Weekly Movement8.1%
Pharmaceuticals Industry Average Movement6.2%
Market Average Movement6.8%
10% most volatile stocks in IN Market9.7%
10% least volatile stocks in IN Market4.4%

Stable Share Price: 531739 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: 531739's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1990118Arihant Baidhttps://www.gennexlab.com

Gennex Laboratories Limited engages in manufacturing and selling of bulk drugs, intermediates, and biotech products. The company offers active pharmaceutical ingredients, including Guaifenesin, Methocarbamol, Fluconazole, Mephenesin, Phenazopyridine Hcl, Melitracen Hcl, Allopurinol, Ketoconazole, Domperidone, Flupentixol Di-Hydrochloride, Chlorphenesin, and Mefanemic Acid. It operates in India, Algeria, Argentina, Bangladesh, Bolivia, Colombia, Ecuador, Egypt, El Salvador, Germany, Guatemala, Iran, Israel, Jordan, Mexico, Nicaragua, Panama City, Peru, Saudi Arabia, Spain, Vietnam, and Yemen.

Gennex Laboratories Fundamentals Summary

How do Gennex Laboratories's earnings and revenue compare to its market cap?
531739 fundamental statistics
Market Cap₹834.92m
Earnings (TTM)₹39.23m
Revenue (TTM)₹625.95m

21.3x

P/E Ratio

1.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
531739 income statement (TTM)
Revenue₹625.95m
Cost of Revenue₹381.03m
Gross Profit₹244.92m
Other Expenses₹205.69m
Earnings₹39.23m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.31
Gross Margin39.13%
Net Profit Margin6.27%
Debt/Equity Ratio23.1%

How did 531739 perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is 531739 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 531739?

Other financial metrics that can be useful for relative valuation.

531739 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.4x
Enterprise Value/EBITDA12.6x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does 531739's PE Ratio compare to its peers?

531739 PE Ratio vs Peers
The above table shows the PE ratio for 531739 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average24.6x
VAISHALI Vaishali Pharma
21.5xn/a₹866.4m
524202 Lactose (India)
35.3xn/a₹865.5m
524506 Coral Laboratories
9.9xn/a₹898.9m
530163 Kerala Ayurveda
31.6xn/a₹746.3m
531739 Gennex Laboratories
21.3xn/a₹834.9m

Price-To-Earnings vs Peers: 531739 is good value based on its Price-To-Earnings Ratio (21.3x) compared to the peer average (24.6x).


Price to Earnings Ratio vs Industry

How does 531739's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

Price-To-Earnings vs Industry: 531739 is good value based on its Price-To-Earnings Ratio (21.3x) compared to the Indian Pharmaceuticals industry average (21.5x)


Price to Earnings Ratio vs Fair Ratio

What is 531739's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

531739 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio21.3x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 531739's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of 531739 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 531739 (₹6.6) is trading below our estimate of fair value (₹72.76)

Significantly Below Fair Value: 531739 is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 531739's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Gennex Laboratories forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


23.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Gennex Laboratories has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine whether Gennex Laboratories is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  • Gennex Laboratories competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Gennex Laboratories performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


24.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 531739 has high quality earnings.

Growing Profit Margin: 531739's current net profit margins (6.3%) are lower than last year (6.7%).


Past Earnings Growth Analysis

Earnings Trend: 531739's earnings have grown significantly by 24.2% per year over the past 5 years.

Accelerating Growth: 531739's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 531739 had negative earnings growth (-2.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (9%).


Return on Equity

High ROE: 531739's Return on Equity (9%) is considered low.


Discover strong past performing companies

Financial Health

How is Gennex Laboratories's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 531739's short term assets (₹471.8M) exceed its short term liabilities (₹242.1M).

Long Term Liabilities: 531739's short term assets (₹471.8M) exceed its long term liabilities (₹31.0K).


Debt to Equity History and Analysis

Debt Level: 531739's net debt to equity ratio (4.1%) is considered satisfactory.

Reducing Debt: 531739's debt to equity ratio has increased from 12.9% to 23.1% over the past 5 years.

Debt Coverage: 531739's debt is well covered by operating cash flow (65.6%).

Interest Coverage: 531739's interest payments on its debt are well covered by EBIT (6.8x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Gennex Laboratories's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 531739's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 531739's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 531739's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 531739's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 531739 has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

7.4yrs

Average management tenure


CEO

Arihant Baid (36 yo)

10.17yrs

Tenure

₹3,028,800

Compensation

Mr. Arihant Baid has been Managing Director of Gennex Laboratories Limited since March 2011 and serves as its Executive Director since May 18, 2012. Mr. Baid serves as Chairman of Gennex Laboratories Limit...


CEO Compensation Analysis

Compensation vs Market: Arihant's total compensation ($USD38.21K) is about average for companies of similar size in the Indian market ($USD38.01K).

Compensation vs Earnings: Arihant's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: 531739's management team is seasoned and experienced (7.4 years average tenure).


Board Members

Experienced Board: 531739's board of directors are considered experienced (9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Gennex Laboratories Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Gennex Laboratories Limited
  • Ticker: 531739
  • Exchange: BSE
  • Founded: 1990
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₹834.920m
  • Shares outstanding: 126.50m
  • Website: https://www.gennexlab.com

Number of Employees


Location

  • Gennex Laboratories Limited
  • Plot No. 144, Akash Ganga
  • 3rd Floor
  • Hyderabad
  • 500073
  • India

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/07/06 00:00
End of Day Share Price2022/07/06 00:00
Earnings2022/03/31
Annual Earnings2022/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.